FOXO Technologies Plans Spin-Off of FOXO Labs Subsidiary

FOXO Technologies Inc. has announced its Board of Directors' approval to spin off its subsidiary FOXO Labs, Inc., which focuses on epigenetics technology that provides health, lifestyle, and longevity insights from saliva-based biomarkers, eliminating the need for invasive blood or urine tests. FOXO Labs holds a patent on a machine learning model that analyzes DNA epigenetic data to assess biochemical states and medical conditions, aiming to integrate these biomarkers into underwriting and consumer engagement tools. CEO Mark White emphasized that the spin-off would better align with the company's business strategy and create value for shareholders by allowing focused development of their cutting-edge epigenetic analysis combined with AI-driven personalized health coaching. Additionally, FOXO Technologies announced a 1-for-1.99 reverse stock split effective July 27, 2025, to maintain compliance with NYSE American listing requirements by ensuring the stock price remains above $0.10 per share, with no expected impact on business operations. This move aims to enhance shareholder value and facilitate the company's long-term strategic goals in the biotechnology space.